Identifying patients with follicular lymphoma who are likely to benefit from an idiotype vaccine

Journal of Clinical Oncology

Volumn 29, Issue 20, 2011, Pages 2748-2749

  Ansell, Stephen M ^a   Suman, Vera J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IMMUNOGLOBULIN M ANTIBODY; PLACEBO; PREDNISONE; RITUXIMAB; TUMOR VACCINE; VINCRISTINE;

ADD ON THERAPY; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER PATIENT; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MANUFACTURE; EDITORIAL; FOLLICULAR LYMPHOMA; HUMAN; HYBRIDOMA; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIOIMMUNOTHERAPY; REMISSION; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR CELL; TUMOR IMMUNITY;

CANCER VACCINES; HUMANS; IMMUNOGLOBULIN IDIOTYPES; LYMPHOMA, FOLLICULAR; PATIENT SELECTION;

EID: 79960237434     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.35.8812     Document Type: Editorial

References (5)

1. Ai WZ, Tibshirani R, Taidi B, et al: Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma. Blood 113:5743-5746, 2009
2. Freedman A, Neelapu SS, Nichols C, et al: Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocytemacrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J Clin Oncol 27:3036-3043, 2009
3. Levy R, Leonard J, Robertson M, et al: Results of a phase 3 trial evaluating safety and efficacy of specific immunotherapy, recombinant idiotype (Id) conjugated to KLH (Id-KLH) with GM-CSF, compared with non-specific immunotherapy, KLH with GM-CSF, in patients with follicular non Hodgkin's lymphoma (FNHL). Ann Oncol 19::iv101-iv102, 2008 (suppl 4)
4. Schuster SJ, Neelapu SS, Gause BL, et al: Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol 29:2787-2794, 2011
5. Bendandi M, Gocke CD, Kobrin CB, et al: Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 5:1171-1177, 1999 (Pubitemid 29474422)